Let’s start up with the current stock price of Beam Therapeutics Inc. (BEAM), which is $72.15 to be very precise. The Stock rose vividly during the last session to $79.795 after opening rate of $79.07 while the lowest price it went was recorded $66.154 before closing at $77.70.
Recently in News on December 5, 2020, Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020. BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Beam Therapeutics Inc. shares are logging -16.54% during the 52-week period from high price, and 455.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $13.00 and $86.45.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1589231 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Beam Therapeutics Inc. (BEAM) recorded performance in the market was 284.80%, having the revenues showcasing 154.14% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.14B, as it employees total of 118 workers.
Specialists analysis on Beam Therapeutics Inc. (BEAM)
During the last month, 0 analysts gave the Beam Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 34.30, with a change in the price was noted +50.64. In a similar fashion, Beam Therapeutics Inc. posted a movement of +235.43% for the period of last 100 days, recording 688,243 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BEAM is recording 0.03 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.02.
Trends and Technical analysis: Beam Therapeutics Inc. (BEAM)
Raw Stochastic average of Beam Therapeutics Inc. in the period of last 50 days is set at 75.73%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 70.91%. In the last 20 days, the company’s Stochastic %K was 83.75% and its Stochastic %D was recorded 89.08%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 284.80%. The shares increased approximately by -0.95% in the 7-day charts and went down by 95.63% in the period of the last 30 days. Common stock shares were driven by 154.14% during last recorded quarter.